Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase-Reference-Cited by-同舟云学术

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Published:2018-05-28 Issue:7 Volume:24 Page:954-960
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ruess Dietrich A.^ORCID,Heynen Guus J.,Ciecielski Katrin J.,Ai Jiaoyu,Berninger Alexandra,Kabacaoglu Derya,Görgülü Kivanc^ORCID,Dantes Zahra,Wörmann Sonja M.,Diakopoulos Kalliope N.,Karpathaki Angeliki F.,Kowalska Marlena,Kaya-Aksoy Ezgi,Song Liang,van der Laan Eveline A. Zeeuw^ORCID,López-Alberca María P.,Nazaré Marc,Reichert Maximilian,Saur Dieter,Erkan Mert M.,Hopt Ulrich T.,Sainz Bruno,Birchmeier Walter,Schmid Roland M.,Lesina Marina,Algül Hana

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0024-8.pdf

Reference53 articles.

1. Neel, B. G., Gu, H. & Pao, L. The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284–293 (2003).

2. Xu, D. & Qu, C.-K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13, 4925–4932 (2008).

3. Chan, G., Kalaitzidis, D. & Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27, 179–192 (2008).

4. Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. & Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100, 1786–1793 (2009).

5. Chan, R. J. & Feng, G.-S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862–867 (2006).

Cited by 299 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

2. KRAS^G^12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening;Molecular Oncology;2024-09-10

3. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09

4. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2024-09

5. ¹⁹Fluorine‐MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer;Journal of Magnetic Resonance Imaging;2024-08-27